Android app on Google Play

Mylan's (MYL) Acqusition of Certain Abbott (ABT) Assets is Credit-Positive Development - Moody's

July 14, 2014 1:49 PM EDT Send to a Friend

Moody's Investors Service commented that Mylan's (Nadaq: MYL) acquisition of a portion of the international established products business from Abbott Laboratories (NYSE: ABT) is credit positive because it will enhance Mylan's scale and diversity while reducing leverage and improving cash flows. However, we expect that Mylan will continue to actively pursue acquisitions which will likely be funded -- at least partly -- with debt. There is no change to Mylan's Baa3 rating or stable outlook. Please go to www.moodys.com for our full Issuer Comment.

The principal methodology used in this rating was Global Pharmaceutical Industry published in December 2012. Please see the Credit Policy page on www.moodys.com for a copy of this methodology.





You May Also Be Interested In


Related Categories

Credit Ratings

Related Entities

Moody's Investors Service, Definitive Agreement

Add Your Comment